CFRX

ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President of Translational Sciences and Preclinical Development

ContraFect Invited to Present New Research Data From Its Pipeline of Direct Lytic Agents at World Microbe Forum

ContraFect Announces Multiple Publications on Exebacase, Including First Manuscript on Local Administration of Lysin for Potential Treatment of Prosthetic Joint Infections

ContraFect Reports First Quarter 2021 Financial Results and Provides Business Update

ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office

ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit

ContraFect Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update